Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_24715 details
Primary information
SALIDSAL_24715
Biomarker namehsa-miRNR-204
Biomarker TypeDiagnostic
Sampling MethodContinuous 2% citric acid tongue stimulation; No eating, drinking, smoking, or oral hygiene procedures for at least 2 h before collection
Collection MethodNA
Analysis MethodqPCR, Microarray, ELISA
Collection SiteSaliva
Disease CategoryGastrointestinal Disorder
Disease/ConditionHelicobacter pylori-associated Gastric Ulcer
Disease SubtypeNA
Fold Change/ ConcentrationNA
Up/DownregulatedNA
ExosomalNA
OrganismHomo sapiens
PMID32019170
Year of Publication2016
Biomarker IDhsa-miRNR-204
Biomarker CategorymiRNA
SequenceNA
Title of studySalivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review
Abstract of studyBackground: The aberrant expression of microRNAs (miRNAs) has been associated with several diseases, including cancer, inflammatory, and autoimmune conditions. Interest in salivary miRNAs as non-invasive tools for the diagnosis of malignancies and systemic diseases is rapidly increasing. The present systematic review was developed for answering the question: "Are salivary microRNAs reliable biomarkers for diagnosis of cancer and systemic diseases?"METHODS: The application of inclusion and exclusion criteria led to the selection of 11 papers. Critical appraisals and quality assessments of the selected studies were performed through the National Institute of Health "Study Quality Assessment Tool" and the classification of the Oxford Center for Evidence-Based Medicine.RESULTS: Seven studies reported statistically significant correlations between one or more salivary miRNAs and the investigated disease. The critical analysis allowed us to classify only two studies (18.2%) as having "good" quality, the rest being scored as "intermediate" (8; 73%) and "poor" (1; 9%). Evidence exists that salivary miR-940 and miR-3679-5p are reliable markers for pancreatic cancer and that miR140-5p and miR301a are promising molecules for the salivary diagnosis of gastric cancer.CONCLUSIONS: Further studies, possibly avoiding the risk of bias highlighted here, are necessary to consolidate these findings and to identify new reliable salivary biomarkers.